Cordis

Endovascular Engineering is a preclinical stage company dedicated to advancing innovative mechanical thrombectomy solutions for peripheral medical conditions. The firm specializes in the development of clot removal technologies specifically designed to address venous thromboembolism, which encompasses critical health issues such as pulmonary embolism and deep vein thrombosis. By focusing on these areas, Endovascular Engineering aims to equip healthcare professionals with efficient and effective tools to enhance patient outcomes in the management of these vascular conditions.

MedAlliance is a privately-owned medical technology company. MedAlliance develops innovative drug-eluting balloons (DEBs) for patients suffering from life-threatening coronary and peripheral arterial disease.

Endovascular Engineering is a preclinical stage company dedicated to advancing innovative mechanical thrombectomy solutions for peripheral medical conditions. The firm specializes in the development of clot removal technologies specifically designed to address venous thromboembolism, which encompasses critical health issues such as pulmonary embolism and deep vein thrombosis. By focusing on these areas, Endovascular Engineering aims to equip healthcare professionals with efficient and effective tools to enhance patient outcomes in the management of these vascular conditions.

Flexible Stenting Solutions, Inc. is a privately held medical device company specializing in the development and commercialization of advanced flexible stents. Utilizing a proprietary design platform, the company has created a third-generation self-expanding stent specifically engineered to withstand the challenging loading conditions found in the superficial femoral and popliteal arteries. This innovative stent features a unique combination of helically wound struts and flexible coils, resulting in high durability, fatigue resistance, superior radial stiffness, and low chronic outward force. The delivery technology emphasizes simplicity and ease of use for medical professionals. Flexible Stenting Solutions has achieved significant regulatory milestones, including CE Mark authorization for its FlexStent® Femoropopliteal and Biliary Self Expanding Stent Systems in January 2009, followed by 510(k) clearance for the FlexStent® Biliary Self Expanding Stent System in September 2009. These stents are designed to provide substantial benefits for patients suffering from malignant biliary strictures, effectively alleviating symptoms associated with biliary obstruction.

Ensure Medical offers a femoral artery closure device that uses a synthetic bioabsorbable polymer to stop bleeding and close the site of the arterial puncture. ACDs are designed to enable expedited closure time and reduce bed-stay when compared to conventional manual compression methods for wound access site closure.

LuMend Inc. designs, develops, manufactures and markets medical devices intended to enable physicians to safely, predictably and cost effectively cross Chronic Total Occlusions (CTO) in the coronary vasculature, allowing subsequent conventional guide wire placement across target stenotic lesions. The company was founded in 1996 by two pioneering interventional cardiologists, John Simpson, PhD, MD, and Matthew Selmon, MD.